Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Blueprint Medicines (BPMC) Stock Price & Analysis
511 Followers
BPMC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$43.89 - $111.99
Previous Close$111.7
Volume343.46K
Average Volume (3M)616.57K
Market Cap
$6.83B
Enterprise Value$6.94B
Total Cash (Recent Filing)$647.90M
Total Debt (Recent Filing)$597.93M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Jul 31, 2024EPS Estimate
-$1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.82
Shares Outstanding62,616,902
10 Day Avg. Volume581,708
30 Day Avg. Volume616,571
Standard Deviation0.14
R-Squared0.07
Alpha0.00661
Financial Highlights & Ratios
Price to Book (P/B)49.97
Price to Sales (P/S)67.90
Price to Cash Flow (P/CF)-20.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue26.25
Enterprise Value/Gross Profit28.83
Enterprise Value/Ebitda-26.70
Forecast
1Y Price Target
$117.77Price Target Upside5.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Blueprint Medicines News
PremiumCompany Announcements
Blueprint Medicines Shareholders Endorse Key Proposals
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBlueprint Medicines Corporation reported total revenues of $96.1MM, higher than consensus estimates of $79.0MM.
Geographic ExpansionGeographic expansion is a key driver for Ayvakit's peak revenue estimate of over $2B.
Revenue GrowthHigh compliance and low discontinuation rates are expected to contribute to Ayvakit's revenue growth.
Bears Say
Earnings GuidanceUpdated guidance suggests a steep drop in patient adds for the remainder of the year.
Market VisibilityLimited visibility into a number of key levers driving results, as well as significant disparity in expectations exiting the quarter.
Pricing TargetThe new price target of $97 is below the current share price of $107.
---
Ownership Overview
16.91% Insiders
45.84% Mutual Funds
17.02% Other Institutional Investors
20.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $43.89 and its highest was $111.99 in the past 12 months.
What is Blueprint Medicines’s market cap?
Currently, no data Available
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is Jul 31, 2024 which is in 25 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on May 02, 2024. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of -$1.666 by $3.116.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -$1.29.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 62,616,900 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of $1.45 in its last earnings report, beating expectations of -$1.666. Following the earnings report the stock price went up 12.798%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 78M.
---
Blueprint Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$117.77 (5.43% Upside)
$117.77 (5.43% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 197.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $679.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.31%
12-Months-Change
Fundamentals
Return on Equity
-79.53%
Trailing 12-Months
Asset Growth
-14.90%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q1 2024
0:00 / 0:00
---
BPMC Stock 12 Month Forecast
Average Price Target
$117.77
▲(5.43% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+18.65%
reiterated a buy rating 6 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +18.65% per trade.
---